United Kingdom’s contribution to European research output in biomedical sciences: 2008–2017

Background: On 31 January 2020, the United Kingdom (UK) formally left the European Union (EU). Only a short transition period, until 31 December 2020, is available to negotiate collaborations for research in biomedical sciences and health care. Within the European scientific community, two opinions...

Full description

Saved in:
Bibliographic Details
Main Authors: Raoul Tan, Eric Sijbrands
Format: Article
Language:English
Published: European Association of Science Editors 2020-05-01
Series:European Science Editing
Subjects:
Online Access:https://ese.arphahub.com/article/51112/download/pdf/
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850168809425469440
author Raoul Tan
Eric Sijbrands
author_facet Raoul Tan
Eric Sijbrands
author_sort Raoul Tan
collection DOAJ
description Background: On 31 January 2020, the United Kingdom (UK) formally left the European Union (EU). Only a short transition period, until 31 December 2020, is available to negotiate collaborations for research in biomedical sciences and health care. Within the European scientific community, two opinions are common: 1) Brexit is an opportunity to obtain more funding at the expense of the departing British; and 2) UK colleagues should continue to collaborate in EU scientific efforts, including Horizon Europe and Erasmus+. To provide evidence for more informed negotiations, we sought to determine the contribution of the UK to EU’s research in biomedical sciences.Methods: We performed a macro level scientometric analysis to estimate the contribution of the UK and EU member states, including those associated with EU-funding (EU+) namely Albania, Armenia, Bosnia-Herzegovina, Faroe Islands, Georgia, Iceland, Israel, Macedonia, Moldova, Montenegro, Norway, Serbia, Switzerland, Tunisia, Turkey, and Ukraine, to preclinical, clinical and health sciences. We searched the Web of Science database to count the total number of scientific publications and the top 1% most cited publications in the world between 2008 and 2017, calculated the performance efficiency by dividing the top 1% by the total number, and calculated the odds ratios to create a ranking of performance efficiency. We then compared the contribution of the UK to all the EU+ -based publications and the top 1% to the contributions of the ten EU member states with the largest biomedical research output and also compared the respective contributions to EU+ publications that resulted from collaborations with other regions in the world.Results: We found 2,991,016 biomedical publications from EU+ during 2008–2017, of which 19,019 (0.64%) were in the world’s top 1% of the most cited publications. The UK produced 665,467 (22.3%) of these publications and had over two and a half times more top 1% most cited publications than the EU+ (odds ratio 2.79, 95% CI 2.71–2.88, p< 0.001). The UK’s share in the EU+ co-publications with regions outside Europe ranged between 23.0% for the Arab League and 50.6% for Australia and New Zealand and its share of the top 1% ranged between 48.6% for the USA and Canada and 70.7% for the African Union.Conclusions: The UK contributed far more highly cited publications than the rest of the EU+ states and strongly contributed to European collaborations with the rest of the world during 2008–2017. This suggests that if the UK ceases to participate in EU scientific collaborations as a result of Brexit, the quantity and quality of EU’s research in biomedical sciences will be adversely affected.
format Article
id doaj-art-aaada19ec5fe4b6c9a054fa2d1afc4e1
institution OA Journals
issn 2518-3354
language English
publishDate 2020-05-01
publisher European Association of Science Editors
record_format Article
series European Science Editing
spelling doaj-art-aaada19ec5fe4b6c9a054fa2d1afc4e12025-08-20T02:20:52ZengEuropean Association of Science EditorsEuropean Science Editing2518-33542020-05-01461410.3897/ese.2020.e5111251112United Kingdom’s contribution to European research output in biomedical sciences: 2008–2017Raoul Tan0Eric Sijbrands1Erasmus MCErasmus MCBackground: On 31 January 2020, the United Kingdom (UK) formally left the European Union (EU). Only a short transition period, until 31 December 2020, is available to negotiate collaborations for research in biomedical sciences and health care. Within the European scientific community, two opinions are common: 1) Brexit is an opportunity to obtain more funding at the expense of the departing British; and 2) UK colleagues should continue to collaborate in EU scientific efforts, including Horizon Europe and Erasmus+. To provide evidence for more informed negotiations, we sought to determine the contribution of the UK to EU’s research in biomedical sciences.Methods: We performed a macro level scientometric analysis to estimate the contribution of the UK and EU member states, including those associated with EU-funding (EU+) namely Albania, Armenia, Bosnia-Herzegovina, Faroe Islands, Georgia, Iceland, Israel, Macedonia, Moldova, Montenegro, Norway, Serbia, Switzerland, Tunisia, Turkey, and Ukraine, to preclinical, clinical and health sciences. We searched the Web of Science database to count the total number of scientific publications and the top 1% most cited publications in the world between 2008 and 2017, calculated the performance efficiency by dividing the top 1% by the total number, and calculated the odds ratios to create a ranking of performance efficiency. We then compared the contribution of the UK to all the EU+ -based publications and the top 1% to the contributions of the ten EU member states with the largest biomedical research output and also compared the respective contributions to EU+ publications that resulted from collaborations with other regions in the world.Results: We found 2,991,016 biomedical publications from EU+ during 2008–2017, of which 19,019 (0.64%) were in the world’s top 1% of the most cited publications. The UK produced 665,467 (22.3%) of these publications and had over two and a half times more top 1% most cited publications than the EU+ (odds ratio 2.79, 95% CI 2.71–2.88, p< 0.001). The UK’s share in the EU+ co-publications with regions outside Europe ranged between 23.0% for the Arab League and 50.6% for Australia and New Zealand and its share of the top 1% ranged between 48.6% for the USA and Canada and 70.7% for the African Union.Conclusions: The UK contributed far more highly cited publications than the rest of the EU+ states and strongly contributed to European collaborations with the rest of the world during 2008–2017. This suggests that if the UK ceases to participate in EU scientific collaborations as a result of Brexit, the quantity and quality of EU’s research in biomedical sciences will be adversely affected.https://ese.arphahub.com/article/51112/download/pdf/Biomedical research in EUBrexitresearch collab
spellingShingle Raoul Tan
Eric Sijbrands
United Kingdom’s contribution to European research output in biomedical sciences: 2008–2017
European Science Editing
Biomedical research in EU
Brexit
research collab
title United Kingdom’s contribution to European research output in biomedical sciences: 2008–2017
title_full United Kingdom’s contribution to European research output in biomedical sciences: 2008–2017
title_fullStr United Kingdom’s contribution to European research output in biomedical sciences: 2008–2017
title_full_unstemmed United Kingdom’s contribution to European research output in biomedical sciences: 2008–2017
title_short United Kingdom’s contribution to European research output in biomedical sciences: 2008–2017
title_sort united kingdom amp rsquo s contribution to european research output in biomedical sciences 2008 amp ndash 2017
topic Biomedical research in EU
Brexit
research collab
url https://ese.arphahub.com/article/51112/download/pdf/
work_keys_str_mv AT raoultan unitedkingdomamprsquoscontributiontoeuropeanresearchoutputinbiomedicalsciences2008ampndash2017
AT ericsijbrands unitedkingdomamprsquoscontributiontoeuropeanresearchoutputinbiomedicalsciences2008ampndash2017